Infantile Fibrosarcoma, from the CureRays guide library.

Infantile fibrosarcoma is a soft-tissue tumor of babies and toddlers that, despite looking aggressive, rarely spreads and is highly curable; it is driven by a specific gene fusion that a targeted pill can shut down, so treatment now often spares infants from intensive chemotherapy and radiation.

What it is.

Infantile fibrosarcoma is a soft-tissue tumor that occurs in the first months and years of life — most are found in babies under one year old, and many are present at birth. A sarcoma is a cancer of the body's connective tissues; infantile fibrosarcoma arises from fibrous tissue and usually appears as a firm, sometimes rapidly enlarging mass in an arm or leg (especially the hands, feet, lower legs, or forearms), and less often in the trunk or head and neck. The mass can grow quickly and look alarming, and the overlying skin may be stretched, red, or even ulcerated, which can raise fear of a very dangerous cancer. The reassuring reality is that infantile fibrosarcoma behaves far more gently than its appearance suggests: it rarely spreads to other parts of the body, and it is one of the most curable cancers of infancy. What makes it distinctive — and what has transformed its treatment — is that the great majority of these tumors are driven by a single specific gene fusion (most often an ETV6-NTRK3 fusion, involving the NTRK gene). Finding this fusion confirms the diagnosis and, crucially, identifies a target. Because the tumor depends on the abnormal NTRK signal, a class of targeted pills called NTRK inhibitors can switch off its growth signal and shrink it dramatically, often allowing doctors to avoid or greatly reduce intensive chemotherapy, large disfiguring surgery, and radiation in a very young child. The modern approach is therefore organized around doing the least harm to a developing baby while curing the tumor: complete surgical removal when it can be done without sacrificing function, targeted therapy or chemotherapy to shrink large tumors first so that surgery can be smaller (or sometimes avoided), and radiation reserved for the uncommon situations where it is truly needed. This represents a real success story in pediatric oncology — a once-worrisome tumor that is now usually cured with treatment tailored to spare the child.

How radiation treats it.

Radiation therapy works by delivering focused beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. For most cancers it is a central treatment, but infantile fibrosarcoma is an important example of when the best use of radiation is to use very little of it. This tumor is highly curable, it rarely spreads, and it occurs in babies and toddlers whose bones, muscles, organs, and growth plates are actively developing and are especially vulnerable to the long-term effects of radiation. Combined with the fact that surgery and, increasingly, a targeted pill can usually cure the tumor, this means radiation is deliberately avoided in the great majority of children — sparing them the late effects on growth and development that radiation could cause. The modern strategy is built around that goal. When the tumor can be removed completely without harming function, surgery alone often cures it. When the tumor is large or awkwardly placed, doctors first shrink it — increasingly with an NTRK-targeted pill that switches off the tumor's driving gene signal, or with relatively gentle chemotherapy — so that a smaller, function-preserving operation becomes possible, again without radiation. Radiation is held in reserve for the uncommon tumor that cannot be controlled by surgery and drug therapy. In those select cases, the radiation is aimed tightly at the tumor area (involved-field) with the field and dose minimized, and proton beam therapy is favored when available because protons deposit their energy in the target and then stop, sparing the growing tissue beyond the tumor and lowering the risk of long-term side effects and second cancers. When protons are not available, intensity-modulated radiation shapes the beams tightly around the target to protect nearby growth plates and organs. In short, radiation's role in infantile fibrosarcoma is defined by restraint: powerful when truly needed, but used as little as possible because gentler, equally curative options come first.

The ways we can treat it.

Radiation generally avoided in infants. Because infantile fibrosarcoma is highly curable with surgery and drug therapy, and because radiation can affect a baby's growing bones, muscles, and organs, radiation is deliberately avoided in most cases — a key principle of treating this favorable tumor.

Focal (involved-field) radiation when truly needed. In the uncommon situation where a tumor can't be controlled otherwise, radiation aimed tightly at the tumor area can help; the field and dose are minimized to protect surrounding developing tissue.

Proton beam radiation therapy. If radiation is required in a young child, protons deposit their energy in the target and stop, sparing growing tissue beyond the tumor and reducing long-term effects and second-cancer risk compared with standard X-ray radiation.

Intensity-modulated radiation (IMRT). When protons are not available and radiation is needed, IMRT shapes photon beams tightly around the target to spare nearby growth plates, muscles, and organs as much as possible.

Questions we hear often.

The tumor grew fast and looks scary — is my baby in danger? It is completely understandable to be frightened, because infantile fibrosarcoma can grow quickly and the overlying skin may be stretched, red, or ulcerated. But this tumor behaves far more gently than it looks. It rarely spreads to other parts of the body, and it is one of the most curable cancers of infancy. With modern treatment — surgery when it can be done safely, and a targeted pill or gentle chemotherapy to shrink large tumors — the great majority of babies are cured. The alarming appearance does not reflect how this particular tumor actually behaves, and the care team will focus on curing it while protecting your child's growth and function.

What is the targeted pill, and why might it replace chemotherapy or radiation? Almost all infantile fibrosarcomas are driven by a single genetic change — most often an ETV6-NTRK3 fusion that produces an abnormal NTRK growth signal. A class of pills called NTRK inhibitors (such as larotrectinib and entrectinib) blocks that exact signal, and they can shrink these tumors dramatically. Because the pill targets the tumor's specific weakness, it can often shrink a large tumor enough to allow a smaller operation — or control the tumor outright — while sparing a baby the broader effects of chemotherapy and the long-term effects of radiation on a developing body. This is why molecular testing for the NTRK fusion is a routine first step, and why targeted therapy increasingly leads the treatment plan.

Will my child need radiation? Most likely not. Radiation is deliberately avoided in the great majority of children with infantile fibrosarcoma, because the tumor is highly curable with surgery and drug therapy and because radiation can affect a baby's growing bones, muscles, and organs. It is reserved for the uncommon tumor that can't be controlled by surgery and targeted therapy or chemotherapy. If radiation does become necessary, the team minimizes the area and dose and favors proton therapy when available to protect your child's developing tissue. The guiding principle is to cure the tumor with the least possible long-term effect on your child.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.